| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5605447 | International Journal of Cardiology | 2017 | 7 Pages |
Abstract
Spironolactone may be associated with higher risks for all-cause and infection-related mortality and HHF in pre-dialysis stage 5 CKD patients. Spironolactone should be used with caution in advanced CKD patients.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Wei-Cheng Tseng, Jia-Sin Liu, Szu-Chun Hung, Ko-Lin Kuo, Yu-Hsin Chen, Der-Cherng Tarng, Chih-Cheng Hsu,